Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 8;12:13550. doi: 10.1038/s41598-022-17767-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

WJ-EV impaired the tumorigenic and metastatic abilities of BCC. (A) The morphology of AT-EV and WJ-EV. (B) Markers of AT-EV and WJ-EV, n = 3. Full-length blots were shown in Supplementary Fig. S3A. (C) The internalization of PKH26-stained AT-EV and WJ-EV into BCC; aBCC, AT-EV-internalized BCC; wBCC, WJ-EV-internalized BCC, n = 3. Images were taken at × 20 magnification. (D) The internalization of AT-EV and WJ-EV into BCC were examined by a flow cytometry, n = 3. (E) The cellular proliferation of AT-EV- and WJ-EV-internalized BCC; aBCC, AT-EV-internalized BCC; wBCC, WJ-EV-internalized BCC, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001. (F) The expression of genes involving in proliferation of BCC, aBCC and wBCC, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001. (G) The protein expression of CDK4 and CDK6 in BCC, aBCC and wBCC, n = 3, ***p < 0.001. Full-length blots were shown in Supplementary Fig. S3B. (H) The sphere formation of BCC and wBCC, n = 3, *p < 0.05, **p < 0.01. Images were taken at × 4 and × 10 magnification. (I) The migration assay of BCC and wBCC, n = 3, *p < 0.05, **p < 0.01. (J) The expression of genes related to EMT and migration in BCC and wBCC, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001. (K) The metastatic ability of BCC and wBCC in vivo. n = 4, ***p < 0.001. (L) The effects of WJ-EV treatment on tumor growth of BCC in vivo. n = 4, **p < 0.01. Raw images of tumors were shown in Supplementary Fig. S4A. All experiments were performed in triplicate.